Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: Rationale and current status

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 3653-3663

  Hraiech, Sami ^a,b   Brégeon, Fabienne ^a,b   Rolain, Jean Marc ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL NORD   (France)

Author keywords

Bacterial infection; Multidrug resistance; Pneumonia; Pulmonary infection

Indexed keywords

ANTIBIOTIC AGENT; LIPOSOME; STREPTOMYCIN; SULFADIAZINE SILVER; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIOPHAGE BASED THERAPY; BIOFILM; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; HUMAN; IN VITRO STUDY; INFECTION SENSITIVITY; LUNG FIBROSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT SAFETY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSEUDOMONAS PNEUMONIA; QUORUM SENSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT FAILURE; WOUND INFECTION; ANIMAL; BACTERIOPHAGE; CYSTIC FIBROSIS; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

ANIMALS; BACTERIOPHAGES; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84937469033     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S53123     Document Type: Review

References (68)

1. Ciofu O, Tolker-Nielsen T, Jensen PO, Wang H, Høiby N. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev. 2014. Epub December 2.
2. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34(2):91–100.
3. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(5):581–588.
4. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;(4)CD004197.
5. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros. 2008;7(6): 523–530.
6. Ciofi Degli AM, Bernaschi P, Carletti M, et al. An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy. BMC Infect Dis. 2014;14:494.
7. Bassetti M, Ginocchio F, Mikulska M. New treatment options against gram-negative organisms. Crit Care. 2011;15(2):215.
8. Hraiech S, Brégeon F, Brunel JM, et al. Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother. 2012;67(10):2452–2458.
9. Hraiech S, Hiblot J, Lafleur J, et al. Inhaled lactonase reduces Pseudomonas aeruginosa quorum sensing and mortality in rat pneumonia. PLoS One. 2014;9(10):e107125.
10. Hurley MN, Cámara M, Smyth AR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J. 2012;40(4):1014–1023.
11. Harper DR, Enright MC. Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J Appl Microbiol. 2011;111(1):1–7.
12. Saussereau E, Vachier I, Chiron R, et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin Microbiol Infect. 2014;20(12):O983–O990.
13. Chanishvili N. Phage therapy – history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res. 2012;83:3–40.
14. Rose T, Verbeken G, Vos DD, et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma. 2014;4(2): 66–73.
15. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009;18(6):237–238, 240–243.
16. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–357.
17. Reardon S. Phage therapy gets revitalized. Nature. 2014;510(7503): 15–16.
18. Berthelot P, Grattard F, Mallaval FO, Ros A, Lucht F, Pozzetto B. [Epidemiology of nosocomial infections due to Pseudomonas aeruginosa, Burkholderia cepacia and Stenotrophomonas maltophilia.] Pathol Biol (Paris). 2005;53(6):341–348. French.
19. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature. 2002;416(6882):740–743.
20. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–1322.
21. Hoyle BD, Alcantara J, Costerton JW. Pseudomonas aeruginosa biofilm as a diffusion barrier to piperacillin. Antimicrob Agents Chemother. 1992;36(9):2054–2056.
22. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5(1):48–56.
23. Gupta K, Marques CN, Petrova OE, Sauer K. Antimicrobial tolerance of Pseudomonas aeruginosa biofilms is activated during an early developmental stage and requires the two-component hybrid SagS. J Bacteriol. 2013;195(21):4975–4987.
24. Doehn JM, Fischer K, Reppe K, et al. Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia. J Antimicrob Chemother. 2013;68(9):2111–2117.
25. Hanlon GW. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents. 2007;30(2):118–128.
26. Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11(1): 69–86.
27. Ojeniyi B, Birch-Andersen A, Mansa B, Rosdahl VT, Høiby N. Morphology of Pseudomonas aeruginosa phages from the sputum of cystic fibrosis patients and from the phage typing set. An electron microscopy study. APMIS. 1991;99(10):925–930.
28. Essoh C, Blouin Y, Loukou G, et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS One. 2013;8(4):e60575.
29. Ceyssens PJ, Lavigne R. Bacteriophages of Pseudomonas. Future Microbiol. 2010;5(7):1041–1055.
30. Selezska K, Kazmierczak M, Müsken M, et al. Pseudomonas aeruginosa population structure revisited under environmental focus: impact of water quality and phage pressure. Environ Microbiol. 2012;14(8): 1952–1967.
31. Friman VP, Ghoul M, Molin S, Johansen HK, Buckling A. Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies. PLoS One. 2013;8(9): e75380.
32. Hraiech S, Roch A, Lepidi H, et al. Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother. 2013;57(10):5120–5121.
33. Koskella B, Lin DM, Buckling A, Thompson JN. The costs of evolving resistance in heterogeneous parasite environments. Proc Biol Sci. 2012; 279(1735):1896–1903.
34. James CE, Fothergill JL, Kalwij H, et al. Differential infection properties of three inducible prophages from an epidemic strain of Pseudomonas aeruginosa. BMC Microbiol. 2012;12:216.
35. Hayashi T, Baba T, Matsumoto H, Terawaki Y. Phage-conversion of cytotoxin production in Pseudomonas aeruginosa. Mol Microbiol. 1990; 4(10):1703–1709.
36. Winstanley C, Langille MG, Fothergill JL, et al. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res. 2009;19(1):12–23.
37. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother. 2010;54(1):397–404.
38. Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol. 2001; 67(6):2746–2753.
39. Costerton JW, Cheng KJ, Geesey GG, et al. Bacterial biofilms in nature and disease. Annu Rev Microbiol. 1987;41:435–464.
40. Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis. 2001;7(2):277–281.
41. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000; 407(6805):762–764.
42. Verma V, Harjai K, Chhibber S. Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae. Biofouling. 2010;26(6):729–737.
43. Glonti T, Chanishvili N, Taylor PW. Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa. J Appl Microbiol. 2010;108(2): 695–702.
44. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–659.
45. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A. 2009; 106(12):4629–4634.
46. Escobar-Páramo P, Gougat-Barbera C, Hochberg ME. Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage. Evol Appl. 2012; 5(6):583–592.
47. Torres-Barceló C, Arias-Sánchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One. 2014;9(9):e106628.
48. Coulter LB, McLean RJ, Rohde RE, Aron GM. Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses. 2014;6(10):3778–3786.
49. Pei R, Lamas-Samanamud GR. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl Environ Microbiol. 2014;80(17):5340–5348.
50. Górski A, Międzybrodzki R, Borysowski J, et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res. 2012;83:41–71.
51. Dabrowska K, Switała-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A. Bacteriophage penetration in vertebrates. J Appl Microbiol. 2005;98(1):7–13.
52. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult Sci. 2003;82(7): 1108–1112.
53. Debarbieux L, Leduc D, Maura D, et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 2010; 201(7):1096–1104.
54. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One. 2011;6(2):e16963.
55. Alemayehu D, Casey PG, McAuliffe O, et al. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio. 2012;3(2):e00029–12.
56. Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother. 2013;57(12):5961–5968.
57. Singla S, Harjai K, Katare OP, Chhibber S. Bacteriophage-Loaded Nanostructured Lipid Carrier: Improved Pharmacokinetics Mediates Effective Resolution of Klebsiella pneumoniae-Induced Lobar Pneumonia. J Infect Dis. 2015. Epub January 20.
58. Carmody LA, Gill JJ, Summer EJ, et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis. 2010;201(2):264–271.
59. Chhibber S, Kaur S, Kumari S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol. 2008;57(Pt 12):1508–1513.
60. Semler DD, Goudie AD, Finlay WH, Dennis JJ. Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. Antimicrob Agents Chemother. 2014;58(7):4005–4013.
61. Bittar F, Rolain JM. Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect. 2010;16(7):809–820.
62. Zhou Z, Duerr J, Johannesson B, et al. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros. 2011;10 Suppl 2:S172–S182.
63. Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009;4(3):e4944.
64. Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect. 2008;38(8):426–430.
65. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010; 28(12):591–595.
66. Golshahi L, Lynch KH, Dennis JJ, Finlay WH. In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J Appl Microbiol. 2011;110(1):106–117.
67. Rolain JM, Fancello L, Desnues C, Raoult D. Bacteriophages as vehicles of the resistome in cystic fibrosis. J Antimicrob Chemother. 2011; 66(11):2444–2447.
68. Northrop JH. Growth and phage production of B. megatherium. I. Growth of cells after infection with C phage. II. Rate of growth, phage yield, and RNA content of cells. III. Effect of various substances on growth rate and phage production. J Gen Physiol. 1953;36(4):581–599